Home - Category: Cancer Research

Category Archives: Cancer Research

A peer reviewed journal that is a breed apart is Oncotarget.

Posted on March 6, 2017 in Cancer Research

Oncology or the study of tumors is a very complicated subject. Finding information on cancer can be very difficult. Luckily, there is one company that researches tumors and simplifies finding information. They even publish their findings online for free every week. That company’s name is Oncotarget. Oncotarget is a peer-reviewed journal that is a subsidiary […]

Understanding Oncology Through Mikhail Blagosklonny

Posted on December 24, 2016 in Cancer Research

Mikhail Blagosklonny is a professor of Oncology at the Roswell Park Cancer Institute. Mikhail is a scientist who studies Aging and Cancer. He went to the First Pavlov State Medical University of St. Petersburg where he earned an MD in Internal Medicine. Mikhail also earned a Ph.D. in Experimental Medicine and Cardiology from the same […]

Clay Siegall is proud of Seattle Genetics

Posted on August 5, 2016 in Cancer Research

  Since the beginning of time, genetics has played a huge role in life. Your genetic makeup can determine your height, skin color, and even which diseases you are susceptible too. For many years, we had no control over genetics, but in the past few decades, doctors and scientist around the globe have started developing genetic therapies. Many doctors believe that genetic therapy could solve issues like cancer, diabetes, and hunger. There are several major companies working on genetic therapies in the United States, and Seattle Genetics is one of the top companies. Seattle Genetics was founded several years ago, with Clay Siegall at the head of the company. They have been developing treatments for Lymphoma and other forms of cancer for several years, and they are starting to turn the corner towards profitability. Recently, Clay Siegall held a meeting with major stakeholders to discuss the results of the last quarter. Clay Siegall is extremely pleased with the faith that investors have placed in his company. He believes that this faith is starting to pay-off. Seattle Genetics’ main product is ADCERTIS. Clay believes that ADCERTIS is well on its way to becoming a major franchise, and will help establish the company as a major oncology firm. ADCERTIS is permanently changing the way that CD30-expressing lymphoma is treated. Seattle Genetics is also working on SGN-CD33A, another major drug. This drug has made it through several major rounds of testing, and it is now entering trials. SGN-CD33A shows hope when it comes to helping AML patients live longer lives. Seattle has many other treatments in the works. These treatments are aimed at everything from breast cancer to urothelial cancer. Clay is highly involved in all of these treatment methods, and he loves watching these potential cures grow. Clay Siegall was happy to report an increase in profits this year. The company earned around $100 million in the second quarter of this year. That is a significant increase for the company. Clay Siegall believes that Seattle Genetics is developing the cures of the future. He believes that investors should remain encouraged when it comes to the future of genetic therapy. Sources: http://seekingalpha.com/article/3991804-seattle-genetics-sgen-clay-b-siegall-q2-2016-results-earnings-call-transcript https://twitter.com/seattlegenetics